We offer a complete range of services, from cell line and strain development through process development and large-scale manufacturing to fill and finish. Our extensive portfolio of capabilities and technologies includes the production of antibodies, recombinant proteins, non-antibody scaffolds, Fab fragments as well as pDNA from either mammalian cell culture or microbial fermentation systems.
Galena Biopharma, a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, announced it has acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide.
Netherlands-based PharmaCell has entered into an agreement with Dendreon to be the contract manufacturing organization (CMO) for the European commercial production of its recently approved cellular immunotherapy product Provenge dispersion for infusion.
The European Patent Office (EPO) has granted Medicago a patent protecting exclusive rights to produce influenza virus-like particles (VLPs) in plants through July 2028.
Bayer HealthCare has launched Xofigo (radium - 223 dichloride) solution for injection in the UK to treat adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.
Research-based pharmaceutical and healthcare company GlaxoSmithKline (GSK) has received a proposal from Aspen Global and Aspen Pharmacare Holdings for its thrombosis brands and Notre-Dame de Bondeville (NDB) site.
Australia-based international biotechnology company Bionomics has commenced manufacturing activities for anti-cancer stem cell candidate BNC10.